Immunotherapy duo takes on tough tumors

NCT ID NCT03911557

Completed Disease control Sponsor: John L. Villano, MD, PhD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tested a combination of two immunotherapy drugs, durvalumab and tremelimumab, in 14 adults with recurrent solid tumors that had a high number of genetic mutations. The goal was to see if the treatment could slow cancer growth compared to their prior therapy. The trial is now complete, and results may help guide future research for patients with these hard-to-treat cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Durvalumab and Tremelimumab (immunotherapy drugs)
What this could lead to: If successful, this could point toward a new treatment option for patients with hard-to-treat solid tumors that have many genetic mutations.
What could go wrong: This was a small, early-phase trial with only 14 participants, so results may not apply to everyone. The drugs can cause immune-related side effects, and the study is already completed without clear breakthrough outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm refractory malignant neoplasm type 1 diabetes mellitus 12

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUMOR, SOLID

Contacts and locations

Locations

Markey Cancer Center

Lexington, Kentucky, 40536, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.